

### CYP2R1 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP7894b

## **Specification**

## CYP2R1 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

# CYP2R1 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 120227

#### **Other Names**

Vitamin D 25-hydroxylase, Cytochrome P450 2R1, CYP2R1

### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/products/AP7894b>AP7894b</a> was selected from the C-term region of human CYP2R1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Q6VVX0

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## CYP2R1 Antibody (C-term) Blocking Peptide - Protein Information

## Name CYP2R1

#### **Function**

A cytochrome P450 monooxygenase involved in activation of vitamin D precursors. Catalyzes hydroxylation at C-25 of both forms of vitamin D, vitamin D(2) and D(3) (calciol) (PubMed:<a href="http://www.uniprot.org/citations/12867411" target="\_blank">12867411</a>, PubMed:<a href="http://www.uniprot.org/citations/15465040" target="\_blank">15465040</a>, PubMed:<a href="http://www.uniprot.org/citations/18511070" target="\_blank">18511070</a>). Can metabolize vitamin D analogs/prodrugs 1alpha-hydroxyvitamin D(2) (doxercalciferol) and 1alpha-hydroxyvitamin D(3) (alfacalcidol) forming 25-hydroxy derivatives (PubMed:<a href="http://www.uniprot.org/citations/15465040" target="\_blank">15465040</a>, PubMed:<a href="http://www.uniprot.org/citations/18511070" target="\_blank">18511070</a>). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:<a



 $href="http://www.uniprot.org/citations/12867411" target="\_blank">12867411</a>, PubMed:<a href="http://www.uniprot.org/citations/15465040" target="\_blank">15465040</a>, PubMed:<a href="http://www.uniprot.org/citations/18511070" target="_blank">18511070</a>).$ 

#### **Cellular Location**

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein

## CYP2R1 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

#### Blocking Peptides

CYP2R1 Antibody (C-term) Blocking Peptide - Images

# CYP2R1 Antibody (C-term) Blocking Peptide - Background

CYP2R1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monoxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This enzyme is a microsomal vitamin D hydroxylase that converts vitamin D into the active ligand for the vitamin D receptor. A mutation in CYP2R1 gene has been associated with selective 25-hydroxyvitamin D deficiency.

## CYP2R1 Antibody (C-term) Blocking Peptide - References

Ramos-Lopez, E., Diabetes Obes Metab 10 (8), 683-685 (2008) Strushkevich, N., J. Mol. Biol. 380 (1), 95-106 (2008) Ramos-Lopez, E., Diabetes Metab. Res. Rev. 23 (8), 631-636 (2007) Nelson, D.R., Pharmacogenetics 14 (1), 1-18 (2004)